Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, appointed Mason Yamashita, vice president, Pharmacovigilance, reporting to David Hagerty, executive vice president, clinical development. “We are pleased to welcome Mason to Conatus and to expand the capabilities of our clinical development team,” said Dr. Hagerty. “Mason brings a wealth of drug development and pharmacovigilance experience that stre...